Reports cash, cash equivalents and marketable securities as of December 31 were $36.1M compared with $85.7M as of December 31, 2023. These ...

Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...

When it comes to recipes, I have a few nonnegotiables: simple, healthy and delicious! These creations are terrific for when you’re craving a quick breakfast or scrumptious afternoon snack: my ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Regeneron Canada, a biotechnology company focused on developing treatments for serious diseases, has reached a pricing and funding agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for ...

The study authors say their findings argue for careful reading of CT scans done for other reasons that may reveal the presence of lung nodules. Imagine you're getting a chest scan for a potential ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy ...

CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...

The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and Arm 2, evaluating THIO as a monotherapy, to ...